Onno van de Stolpe, Galapagos CEO (Thierry Roge/Belga Mag/AFP via Getty Images)

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months af­ter Gilead gut­ted its rich part­ner­ship with Gala­pa­gos fol­low­ing a bit­ter set­back at the FDA, the Bel­gian biotech is hun­ker­ing down …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.